The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial

BACKGROUND: P2X3 receptor antagonists seem to have a promising potential for treating patients with refractory chronic cough. In this double-blind, randomized, placebo-controlled study, we investigated the efficacy, safety, and tolerability of the novel selective P2X3 receptor antagonist filapixant...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedrich, Christian, Francke, Klaus, Birring, Surinder S., van den Berg, Jan Willem K., Marsden, Paul A., McGarvey, Lorcan, Turner, Alice M., Wielders, Pascal, Gashaw, Isabella, Klein, Stefan, Morice, Alyn H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088222/
https://www.ncbi.nlm.nih.gov/pubmed/37041539
http://dx.doi.org/10.1186/s12931-023-02384-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088222/
https://www.ncbi.nlm.nih.gov/pubmed/37041539
http://dx.doi.org/10.1186/s12931-023-02384-8

Ejemplares similares